Brentuximab vedotin in CD30+lymphomas: single center experience

被引：0
|
作者：
Aydin, M. [1 ]
Okay, M. [2 ]
Ciftciler, R. [2 ]
Aladag, E. [2 ]
Aksu, S. [2 ]
Demiroglu, H. [2 ]
Goker, H. [2 ]
Buyukasik, Y. [2 ]
Ozcebe, O. [2 ]
Haznedaroglu, I. [2 ]
Sayinalp, N. [2 ]
机构：
[1] Ankara Numune Training & Res Hosp, Ankara, Turkey
[2] Hacettepe Univ Hematol, Ankara, Turkey
来源：
LEUKEMIA RESEARCH | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP-50
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [1] SINGLE UK CENTRE EXPERIENCE OF BRENTUXIMAB VEDOTIN MONOTHERAPY IN REFRACTORY CD30+LYMPHOMAS
    Gibb, A.
    Jones, C.
    Bloor, A.
    Kulkarni, S.
    Linton, K.
    Illidge, T.
    Radford, J.
    HAEMATOLOGICA, 2012, 97 : 436 - 436
  • [2] Brentuximab vedotin: new treatment for CD30+lymphomas
    Terriou, Louis
    Bonnet, Sarah
    Debarri, Houria
    Demarquette, Helene
    Morschhauser, Franck
    BULLETIN DU CANCER, 2013, 100 (7-8) : 775 - 779
  • [3] BRENTUXIMAB VEDOTIN IN THE TREATMENT FOR HEMOPHAGOCYTIC SYNDROME SECONDARY TO CD30+LYMPHOMAS
    Buendia, Urena Buenaventura
    Gutierrez, Lopez De Ocariz Xabier
    De Nicolas, Sol Rodrigo
    Lopez, Munoz Nieves
    Vera, Guerrero Elena
    Hidalgo, Soto Marta
    Poza, Santaella Maria
    Zamanillo, Herreros Irene
    Iniguez, Garcia Rodrigo
    Sanchez, Pina Jose Maria
    Redondo, Velao Sara
    Calbacho, Robles Maria
    Jimenez, Ubieto Ana
    Rodriguez, Izquierdo Antonia
    Martinez, Lopez Joaquin
    HAEMATOLOGICA, 2020, 105 : 328 - 328
  • [4] Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas
    Illidge, Tim
    Bouabdallah, Reda
    Chen, Robert W.
    Gopal, Ajay K.
    Moskowitz, Craig H.
    Ramchandren, Radhakrishnan
    Rosenblatt, Joseph D.
    Shustov, Andrei R.
    Tilly, Herve
    Trippett, Tanya
    Grove, Laurie E.
    Advani, Ranjana H.
    BLOOD, 2011, 118 (21) : 1335 - 1336
  • [5] Brentuximab vedotin for the treatment of CD30+ lymphomas
    Foyil, Kelley V.
    Bartlett, Nancy L.
    IMMUNOTHERAPY, 2011, 3 (04) : 475 - 485
  • [6] Clinical Responses to CAR.CD30-T Cells in Patients with CD30+Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin
    Grover, Natalie S.
    Park, Steven I.
    Ivanova, Anastasia
    Eldridge, Paul
    McKay, Kathryn
    Cheng, Catherine Joyce Arago
    Laing, Spencer
    Covington, Deborah
    West, John
    Sharf, S. Elizabeth
    Morrison, J. Kaitlin
    Scott, Shaw
    Crecelius, Erin
    Shelley, Desirae
    Alexander, Maurice
    Buchanan, Faith Brianne
    Kassam, Emily Herrick
    McElfresh, Megan
    Pinto, Alicia R.
    Spruill, Angela Denise
    Zanter, Ashley
    Wehner, Kimberly
    Dittus, Christopher
    Shea, Thomas C.
    Dotti, Gianpietro
    Serody, Jonathan S.
    Beaven, Anne
    Savoldo, Barbara
    BLOOD, 2018, 132
  • [7] Brentuximab Vedotin in Combination with Nivolumab in CD30+Malignancies Refractory to Brentuximab Vedotin
    Poh, Christina
    Lynch, Ryan C.
    Warren, Edus H.
    Ujjani, Chaitra S.
    Smith, Stephen D.
    Shinohara, Michi M.
    Fromm, Jonathan R.
    Fan, Xinyi
    Voutsinas, Jenna M.
    Wu, Qian
    Naylor, Laura
    Rasmussen, Heather
    Gopal, Ajay K.
    BLOOD, 2023, 142
  • [8] Intralesional brentuximab vedotin: our experience in the treatment of CD30+primary cutaneous T-cell lymphomas
    Arroyo Andres, J. A.
    Rubio Muniz, C. A.
    Agud De Dios, M. A.
    Falkenhain Lopez, D.
    Mitsunaga, K.
    Sanchez Velazquez, A.
    Postigo Llorente, C.
    Ortiz-Romero, P. L.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S50 - S51
  • [9] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: SINGLE CENTER EXPERIENCE
    Valiev, Timur
    Tsaplina, Nataly
    Kirgizov, Kirill
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S589 - S589
  • [10] Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
    Younes, Anas
    Bartlett, Nancy L.
    Leonard, John P.
    Kennedy, Dana A.
    Lynch, Carmel M.
    Sievers, Eric L.
    Forero-Torres, Andres
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19): : 1812 - 1821
12345